Jorg H.W. Distler and Oliver Distler Pages 305 - 308 ( 4 )
In the last years, several key-pathways for the aberrant activation of fibroblasts in SSc have been identified in pre-clinical studies. This review summarizes recently identified molecular targets for novel anti-fibrotic approaches in systemic sclerosis (SSc) and other fibrotic disorders. We will focus on pathways that can be targeted by drugs that are either already approved for other indications or that are currently evaluated in clinical trials.
Fibrosis, scleroderma, molecular-targeted therapies, Anti-Fibrotic Approaches, Systemic Sclerosis, 5-hydroxy-trypthamine, pro-fibrotic effects, tight-skin 1 (tsk-1), HISTONE DEACETYLASE INHIBITORS, Hyperacetylation, HDACs, anti-fibrotic effects, transcriptional coactivators, multiple malignancies, neoplastic diseases, leukaemia, procainamide, hydralazine, cardiac arrhythmias, RE-CEPTOR γ AGONISTS, PPARγ agonists, Sonic Hedgehog (Shh)
Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Germany.